Identification of 2-[2-(4-tert-butylphenyl)ethyl]-N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide (29) as an orally available MGAT2 inhibitor.

Abstract

MGAT2 (monoacylglycerol acyltransferase 2) is expected to be an attractive target for the drug treatment of obesity, diabetes, and other disease. We describe our exploration and structure-activity relationship (SAR) study of 2,3-dihydro-1H-isoindole-5-sulfonamide derivatives. In this study, we identified 29 as an orally available inhibitor of MGAT2 through optimization especially in terms of solubility. This compound exhibited moderate potency in the enzyme inhibitory assay (IC50 = 1522 nM) and significant suppression of fat absorption (57% inhibition) in mice oral lipid tolerance test.

• Authors: Tsuyoshi Busujima, Hiroaki Tanaka, Yoshihisa Shirasaki, Eiji Munetomo, Masako Saito, Kiyokazu Kitano, Toshiya Minagawa, Koji Yoshida, Naoto Osaki, Nagaaki Sato
• Journal: Bioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 23 Issue 17 Pg. 5922-31 (Sep 01 2015) ISSN: 1464-3391 [Electronic] England
• PMID: 26210160 (Publication Type: Journal Article)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Sulfonamides
• Tetrahydroisoquinolines
• N-Acetylglucosaminyltransferases
• alpha-1,6-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase

Topics

• Animals
• Diabetes Mellitus (drug therapy)
• Humans
• Mice
• N-Acetylglucosaminyltransferases (antagonists & inhibitors)
• Obesity (drug therapy)
• Structure-Activity Relationship
• Sulfonamides (chemistry)
• Tetrahydroisoquinolines (chemistry)